Quest Partners LLC Purchases 32,884 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Quest Partners LLC lifted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2,791.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 34,062 shares of the company's stock after purchasing an additional 32,884 shares during the period. Quest Partners LLC's holdings in IDEAYA Biosciences were worth $1,079,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in IDEAYA Biosciences during the 1st quarter valued at $101,000. Vanguard Group Inc. boosted its position in IDEAYA Biosciences by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company's stock valued at $182,355,000 after buying an additional 679,985 shares during the period. Covestor Ltd boosted its position in IDEAYA Biosciences by 9,225.0% during the 1st quarter. Covestor Ltd now owns 1,119 shares of the company's stock valued at $49,000 after buying an additional 1,107 shares during the period. Ameritas Investment Partners Inc. boosted its position in IDEAYA Biosciences by 5.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company's stock valued at $288,000 after buying an additional 332 shares during the period. Finally, O Shaughnessy Asset Management LLC purchased a new stake in IDEAYA Biosciences during the 1st quarter valued at $214,000. Institutional investors own 98.29% of the company's stock.

Wall Street Analyst Weigh In

IDYA has been the subject of several research analyst reports. UBS Group initiated coverage on shares of IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a "buy" rating and a $50.00 target price for the company. Stephens initiated coverage on shares of IDEAYA Biosciences in a research report on Monday. They issued an "overweight" rating and a $51.00 target price for the company. Wedbush reaffirmed an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, IDEAYA Biosciences has an average rating of "Moderate Buy" and a consensus target price of $53.67.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA opened at $25.54 on Thursday. The firm has a market cap of $2.21 billion, a P/E ratio of -10.96 and a beta of 0.86. IDEAYA Biosciences, Inc. has a fifty-two week low of $25.35 and a fifty-two week high of $47.74. The firm has a 50-day simple moving average of $30.79 and a two-hundred day simple moving average of $36.00.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.03. During the same quarter in the prior year, the business earned ($0.46) earnings per share. On average, equities research analysts predict that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.